Comprehensive Review Shows Gut Microbiome Influences Immunotherapy Efficacy
Scientists have for long been concerned about why some people with liver cancer respond when given immunotherapy but others don’t. A recent comprehensive review provides key insights linking how patients respond to these treatments to the status of their gut microbiome. The review, published in the journal Cancer Biology and Medicine, was conducted by a team based at the Chinese University of Hong Kong. The scientists compiled recent scientific data detailing how the microbial composition of the gut impacts how different patients respond when they are given immune checkpoint blockade therapies against hepatocellular carcinoma, the most common type of liver cancer. They found that anti-tumor immune activity is modulated or influenced…
